Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: FTT001
MIFTS: 66

Fatty Liver Disease

Categories: Gastrointestinal diseases, Liver diseases, Metabolic diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Fatty Liver Disease

About this section

MalaCards integrated aliases for Fatty Liver Disease:

Name: Fatty Liver Disease 12 43 15
Fatty Liver 76 55 44 73
Fatty Liver, Alcoholic 44 73
Alcoholic Fatty Liver 12 15
Fatty Change of Liver 12
Fatty Liver Alcoholic 55
Steatosis of Liver 12
Hepatic Lipidosis 12
Steatohepatitis 73

Classifications:

MalaCards categories:
Global: Metabolic diseases
Anatomical: Gastrointestinal diseases Liver diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:9452
ICD10 33 K70.0
ICD9CM 35 571.0
SNOMED-CT 68 50325005 5360002
Sources

Summaries for Fatty Liver Disease

About this section
MedlinePlus : 43 What is fatty liver disease? Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. Fatty liver disease is a condition in which fat builds up in your liver. There are two main types: Nonalcoholic fatty liver disease (NAFLD) Alcoholic fatty liver disease, also called alcoholic steatohepatitis What is nonalcoholic fatty liver disease (NAFLD)? NAFLD is a type of fatty liver disease that is not related to heavy alcohol use. There are two kinds: Simple fatty liver, in which you have fat in your liver but little or no inflammation or liver cell damage. Simple fatty liver typically does not get bad enough to cause liver damage or complications. Nonalcoholic steatohepatitis (NASH), in which you have inflammation and liver cell damage, as well as fat in your liver. Inflammation and liver cell damage can cause fibrosis, or scarring, of the liver. NASH may lead to cirrhosis or liver cancer. What is alcoholic fatty liver disease? Alcoholic fatty liver disease is due to heavy alcohol use. Your liver breaks down most of the alcohol you drink, so it can be removed from your body. But the process of breaking it down can generate harmful substances. These substances can damage liver cells, promote inflammation, and weaken your body's natural defenses. The more alcohol that you drink, the more you damage your liver. Alcoholic fatty liver disease is the earliest stage of alcohol-related liver disease. The next stages are alcoholic hepatitis and cirrhosis. Who is at risk for fatty liver disease? Researchers do not know the cause of nonalcoholic fatty liver (NAFLD). They do know that it is more common in people who Have type 2 diabetes and prediabetes Have obesity Are middle aged or older (although children can also get it) Are Hispanic, followed by non-Hispanic whites. It is less common in African Americans. Have high levels of fats in the blood, such as cholesterol and triglycerides Have high blood pressure Take certain drugs, such as corticosteroids and some cancer drugs Have certain metabolic disorders, including metabolic syndrome Have rapid weight loss Have certain infections, such as hepatitis C Have been exposed to some toxins NAFLD affects about 25 percent of people in the world. As the rates of obesity, type 2 diabetes, and high cholesterol are rising in the United States, so is the rate of NAFLD. NAFLD is the most common chronic liver disorder in the United States. Alcoholic fatty liver disease only happens in people who are heavy drinkers, especially those who have been drinking for a long period of time. The risk is higher for heavy drinkers who are women, have obesity, or have certain genetic mutations. What are the symptoms of fatty liver disease? Both NAFLD and alcoholic fatty liver disease are usually silent diseases with few or no symptoms. If you do have symptoms, you may feel tired or have discomfort in the upper right side of your abdomen. How is fatty liver disease diagnosed? Because there are often no symptoms, it is not easy to find fatty liver disease. Your doctor may suspect that you have it if you get abnormal results on liver tests that you had for other reasons. To make a diagnosis, your doctor will use Your medical history A physical exam Various tests, including blood and imaging tests, and sometimes a biopsy As part of the medical history, your doctor will ask about your alcohol use, to find out whether fat in your liver is a sign of alcoholic fatty liver disease or nonalcoholic fatty liver (NAFLD). He or she will also ask which medicines you take, to try to determine whether a medicine is causing your NAFLD. During the physical exam, your doctor will examine your body and check your weight and height. Your doctor will look for signs of fatty liver disease, such as An enlarged liver Signs of cirrhosis, such as jaundice, a condition that causes your skin and whites of your eyes to turn yellow You will likely have blood tests, including liver function tests and blood count tests. In some cases you may also have imaging tests, like those that check for fat in the liver and the stiffness of your liver. Liver stiffness can mean fibrosis, which is scarring of the liver. In some cases you may also need a liver biopsy to confirm the diagnosis, and to check how bad the liver damage is. What are the treatments for fatty liver disease? Doctors recommend weight loss for nonalcoholic fatty liver. Weight loss can reduce fat in the liver, inflammation, and fibrosis. If your doctor thinks that a certain medicine is the cause of your NAFLD, you should stop taking that medicine. But check with your doctor before stopping the medicine. You may need to get off the medicine gradually, and you might need to switch to another medicine instead. There are no medicines that have been approved to treat NAFLD. Studies are investigating whether a certain diabetes medicine or Vitamin E can help, but more studies are needed. The most important part of treating alcohol-related fatty liver disease is to stop drinking alcohol. If you need help doing that, you may want to see a therapist or participate in an alcohol recovery program. There are also medicines that can help, either by reducing your cravings or making you feel sick if you drink alcohol. Both alcoholic fatty liver disease and one type of nonalcoholic fatty liver disease (nonalcoholic steatohepatitis) can lead to cirrhosis. Doctors can treat the health problems caused by cirrhosis with medicines, operations, and other medical procedures. If the cirrhosis leads to liver failure, you may need a liver transplant. What are some lifestyle changes that can help with fatty liver disease? If you have any of the types of fatty liver disease, there are some lifestyle changes that can help: Eat a healthy diet, limiting salt and sugar, plus eating lots of fruits, vegetables, and whole grains Get vaccinations for hepatitis A and B, the flu and pneumococcal disease. If you get hepatitis A or B along with fatty liver, it is more likely to lead to liver failure. People with chronic liver disease are more likely to get infections, so the other two vaccinations are also important. Get regular exercise, which can help you lose weight and reduce fat in the liver Talk with your doctor before using dietary supplements, such as vitamins, or any complementary or alternative medicines or medical practices. Some herbal remedies can damage your liver.

MalaCards based summary : Fatty Liver Disease, also known as fatty liver, is related to fatty liver disease, nonalcoholic 1 and nonalcoholic fatty liver disease. An important gene associated with Fatty Liver Disease is MALAT1 (Metastasis Associated Lung Adenocarcinoma Transcript 1), and among its related pathways/superpathways are Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. and Developmental Biology. The drugs Tocopherol and Amlodipine have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and heart, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 A lipid storage disease characterized by the accumulation of large vacuoles of triglyceride fat in liver cells via the process of steatosis.

Wikipedia : 76 Fatty liver, or hepatic steatosis or simple steatosis, is a reversible condition wherein large vacuoles... more...

Sources

Related Diseases for Fatty Liver Disease

About this section

Diseases related to Fatty Liver Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 401)
# Related Disease Score Top Affiliating Genes
1 fatty liver disease, nonalcoholic 1 34.5 ADIPOQ INS LEP PPARA SREBF1
2 nonalcoholic fatty liver disease 34.2 ADIPOQ CYP2E1 IL6 INS LEP MLXIPL
3 nonalcoholic steatohepatitis 33.5 ADIPOQ CYP2E1 INS LEP PNPLA3 TNF
4 liver disease 32.8 ADIPOQ ADIPOR2 CYP2E1 IL6 INS LEP
5 lipid metabolism disorder 30.9 ADIPOQ INS LEP PPARA
6 chronic kidney failure 30.8 ADIPOQ IL6 INS LEP
7 morbid obesity 30.8 ADIPOQ INS LEP LEPR
8 sleep apnea 30.7 ADIPOQ IL1B IL6 INS LEP LEPR
9 arteries, anomalies of 30.6 ADIPOQ IL1B IL6 INS LEP TNF
10 atherosclerosis susceptibility 30.6 ADIPOQ IL6 INS PPARA TNF
11 glucose intolerance 30.6 ADIPOQ INS IRS1 LEP LEPR
12 liver cirrhosis 30.6 ADIPOQ CYP2E1 LEP MALAT1
13 vascular disease 30.5 ADIPOQ IL6 INS TNF
14 periodontitis 30.5 IL1B IL6 TNF
15 diabetes mellitus 30.4 ADIPOQ IL1B IL6 INS IRS1 IRS2
16 diabetes mellitus, noninsulin-dependent 30.3 ADIPOQ ADIPOR1 ADIPOR2 IL6 INS IRS1
17 pancreas disease 30.2 IL6 INS LEP TNF
18 insulin-like growth factor i 30.2 INS IRS1 IRS2 LEP
19 apnea, obstructive sleep 30.2 ADIPOQ IL6 INS LEP TNF
20 prader-willi syndrome 30.2 ADIPOQ INS LEP LEPR
21 osteoporosis 30.2 ADIPOQ IL1B IL6 INS LEP LEPR
22 protein-energy malnutrition 30.1 IL6 LEP TNF
23 lipid storage disease 30.1 ADIPOQ INS PNPLA3 SREBF1
24 hyperglycemia 30.0 ADIPOQ INS IRS1 LEP MALAT1
25 eating disorder 30.0 ADIPOQ LEP LEPR
26 alcoholic hepatitis 30.0 CYP2E1 IL6 TNF
27 gestational diabetes 29.9 ADIPOQ ADIPOR1 INS IRS1 IRS2 LEP
28 3-hydroxyacyl-coa dehydrogenase deficiency 29.9 ADIPOQ INS LEP PPARA
29 arteriosclerosis 29.9 ADIPOQ IL6 INS PPARA
30 diabetes mellitus, insulin-dependent 29.8 IL1B IL6 INS LEP
31 body mass index quantitative trait locus 11 29.8 ADIPOQ ADIPOR1 ADIPOR2 CYP2E1 IL6 INS
32 pre-eclampsia 29.6 ADIPOQ IL6 LEP LEPR MALAT1 TNF
33 pertussis 29.6 IL1B IL6 TNF
34 overnutrition 29.6 ADIPOQ IL6 INS IRS1 LEP LEPR
35 maturity-onset diabetes of the young, type 1 29.5 ADIPOQ IL6 INS IRS1 IRS2 LEP
36 fatty liver disease, nonalcoholic 2 12.4
37 long-chain 3-hydroxyacyl-coa dehydrogenase deficiency 12.2
38 congenital generalized lipodystrophy 11.3
39 visceral steatosis 11.3
40 visceral steatosis, congenital 11.3
41 corticosteroid-binding globulin deficiency 11.1
42 morbid obesity and spermatogenic failure 11.0
43 neutral lipid storage disease with myopathy 10.9
44 combined oxidative phosphorylation deficiency 16 10.9
45 hepatocellular carcinoma 10.6
46 hepatitis 10.6
47 polycystic ovary syndrome 10.4
48 hepatitis c 10.4
49 scorpion envenomation 10.4 IL6 TNF
50 hepatitis b 10.4

Comorbidity relations with Fatty Liver Disease via Phenotypic Disease Network (PDN):


Alcohol Abuse Alcoholic Hepatitis
Alcoholic Liver Cirrhosis

Graphical network of the top 20 diseases related to Fatty Liver Disease:



Diseases related to Fatty Liver Disease
Sources

Symptoms & Phenotypes for Fatty Liver Disease

About this section

GenomeRNAi Phenotypes related to Fatty Liver Disease according to GeneCards Suite gene sharing:

26 (show all 19)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.72 IRS2
2 Increased shRNA abundance (Z-score > 2) GR00366-A-113 9.72 LEP
3 Increased shRNA abundance (Z-score > 2) GR00366-A-124 9.72 XBP1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.72 IRS2 LEP NR1H3 XBP1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.72 XBP1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-138 9.72 XBP1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.72 XBP1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.72 IRS2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-183 9.72 NR1H3
10 Increased shRNA abundance (Z-score > 2) GR00366-A-192 9.72 XBP1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-194 9.72 NR1H3
12 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.72 LEP XBP1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.72 IRS2 NR1H3
14 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.72 IRS2 XBP1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-46 9.72 NR1H3
16 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.72 IRS2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-54 9.72 NR1H3
18 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.72 IRS2
19 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.72 IRS2

MGI Mouse Phenotypes related to Fatty Liver Disease:

46 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.49 ADIPOQ ADIPOR1 ADIPOR2 CYP2E1 IL1B IL6
2 adipose tissue MP:0005375 10.43 ADIPOQ ADIPOR1 ADIPOR2 IL6 INS IRS1
3 cardiovascular system MP:0005385 10.41 ADIPOQ CYP2E1 IL1B IL6 INS IRS1
4 liver/biliary system MP:0005370 10.41 ADIPOQ ADIPOR1 ADIPOR2 CYP2E1 IL6 INS
5 cellular MP:0005384 10.4 ADIPOQ ADIPOR1 ADIPOR2 IL6 INS IRS1
6 behavior/neurological MP:0005386 10.39 ADIPOQ ADIPOR1 ADIPOR2 CYP2E1 IL6 INS
7 growth/size/body region MP:0005378 10.38 ADIPOQ ADIPOR1 ADIPOR2 IL1B IL6 INS
8 mortality/aging MP:0010768 10.34 ADIPOQ CYP2E1 IL1B IL6 INS IRS1
9 endocrine/exocrine gland MP:0005379 10.33 ADIPOQ ADIPOR2 IL6 INS IRS1 IRS2
10 immune system MP:0005387 10.31 ADIPOQ IL1B IL6 INS IRS1 IRS2
11 hematopoietic system MP:0005397 10.26 ADIPOQ IL1B IL6 INS IRS1 LEP
12 integument MP:0010771 10.22 ADIPOQ IL1B IL6 INS IRS2 LEP
13 muscle MP:0005369 10.22 ADIPOQ ADIPOR1 IL6 INS IRS1 IRS2
14 nervous system MP:0003631 10.1 ADIPOQ ADIPOR2 IL1B IL6 INS IRS2
15 neoplasm MP:0002006 9.97 ADIPOQ CYP2E1 IL1B IL6 LEP LEPR
16 reproductive system MP:0005389 9.81 ADIPOR2 IL6 INS IRS2 LEP LEPR
17 renal/urinary system MP:0005367 9.8 ADIPOQ IL6 INS IRS2 LEP LEPR
18 skeleton MP:0005390 9.7 ADIPOQ ADIPOR1 ADIPOR2 IL1B IL6 INS
19 vision/eye MP:0005391 9.23 ADIPOR1 IL6 INS LEP LEPR MAPK8
Sources

Drugs & Therapeutics for Fatty Liver Disease

About this section

Drugs for Fatty Liver Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 351)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tocopherol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1406-66-2 14986
2
Amlodipine Approved Phase 4 88150-42-9 2162
3
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
4
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
5
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
6
Insulin Glargine Approved Phase 4,Phase 2 160337-95-1
7
Zinc Approved, Investigational Phase 4,Phase 2,Not Applicable 7440-66-6
8
Exenatide Approved, Investigational Phase 4,Phase 2,Phase 3 141758-74-9 15991534
9
Ethanol Approved Phase 4,Phase 3,Phase 2,Not Applicable 64-17-5 702
10
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 657-24-9 14219 4091
11
Ezetimibe Approved Phase 4,Phase 2 163222-33-1 150311
12
Liraglutide Approved Phase 4,Phase 3,Phase 2 204656-20-2 44147092
13
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 111025-46-8 4829
14
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7439-89-6 23925
15
Peginterferon alfa-2a Approved, Investigational Phase 4,Not Applicable 198153-51-4 5360545
16
Ribavirin Approved Phase 4,Not Applicable 36791-04-5 37542
17
Rosiglitazone Approved, Investigational Phase 4,Phase 2,Not Applicable 122320-73-4 77999
18
Insulin Detemir Approved Phase 4 169148-63-4 5311023
19
Insulin Aspart Approved Phase 4 116094-23-6 16132418
20
Tamoxifen Approved Phase 4 10540-29-1 2733526
21
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
22
Gliclazide Approved Phase 4 21187-98-4 3475
23
Rifampicin Approved Phase 4,Phase 1 13292-46-1 5458213 5381226
24 tannic acid Approved Phase 4,Phase 3,Not Applicable
25
Benzocaine Approved, Investigational Phase 4,Phase 3,Not Applicable 94-09-7, 1994-09-7 2337
26
Empagliflozin Approved Phase 4,Not Applicable 864070-44-0
27
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
28
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
29
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
30
Rifaximin Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 80621-81-4 6436173
31
Glimepiride Approved Phase 4 93479-97-1 3476
32 Dulaglutide Approved, Investigational Phase 4,Not Applicable 923950-08-7
33
Saxagliptin Approved Phase 4 361442-04-8 11243969
34
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-02-9 14985
35
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 59-30-3 6037
36
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 65-23-6 1054
37
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 50-14-6 5280793
38
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 1406-16-2
39
Methionine Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 63-68-3 6137
40
Vitamin D3 Approved, Nutraceutical Phase 4,Phase 3,Phase 2 67-97-0 5280795 6221
41
Ginseng Approved, Investigational, Nutraceutical Phase 4,Not Applicable 50647-08-0
42 Tocotrienol Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 6829-55-6
43
2,4-thiazolidinedione Investigational Phase 4,Phase 2 2295-31-0
44
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
45 Tocotrienols Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Liver Extracts Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
47 Tocopherols Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Angiotensin-Converting Enzyme Inhibitors Phase 4
49
protease inhibitors Phase 4,Phase 2,Phase 1,Not Applicable
50 Vasodilator Agents Phase 4,Phase 3,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 721)
# Name Status NCT ID Phase Drugs
1 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
2 Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease Unknown status NCT02213224 Phase 4 Perindopril;Telmisartan;Amlodipine
3 The Effect Of Dual Treatment With L-Carnitine And Magnesium On Fatty Liver Unknown status NCT01956825 Phase 4
4 Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes Unknown status NCT02303730 Phase 4 Exenatide;insulin glargine
5 Atorvastatin Versus Vitamin E in Treatment of Non-alcoholic Fatty Liver Disease Unknown status NCT01720719 Phase 4 atorvastatin;Vitamin E
6 Effect of Metadoxine on Oxidative Stress in Non-alcoholic Hepatic Steatosis Unknown status NCT02051842 Phase 4 Metadoxine
7 Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
8 Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism Unknown status NCT02721888 Phase 4 Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
9 Trial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4 Metformin
10 Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects Completed NCT02147925 Phase 4 Liraglutide combined with metformin;Insulin glargine combined with metformin;Sitagliptin combined with metformin
11 Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease Completed NCT01006889 Phase 4 Exenatide
12 University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial) Completed NCT00994682 Phase 4 Pioglitazone study drug;Placebo;Pioglitazone Open Label
13 Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment Completed NCT01002547 Phase 4 pioglitazone-placebo;pioglitazone;pioglitazone-placebo;Vitamin E-placebo
14 The Effect of Vitamin D Supplementation in Type 2 Diabetes Completed NCT01854463 Phase 4 Vitamin D3;placebo
15 Liver Safety Under Upfront Arimidex vs Tamoxifen Completed NCT00537771 Phase 4 Anastrozole;Tamoxifen
16 Antidiabetic Effects on Intrahepatic Fat Completed NCT03068065 Phase 4 Liraglutide;Metformin;Gliclazide
17 Effects of Exenatide (Byetta®) on Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT01208649 Phase 4 Exenatide
18 A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD Completed NCT02285205 Phase 4 Oral administration of Lobeglitazone
19 The Effects of PXR Activation on Hepatic Fat Content Completed NCT02329405 Phase 4 Rifampicin;Placebo
20 Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone Completed NCT02875821 Phase 4 Ipragliflozin;metformin with pioglitazone
21 Impact of Short-term Fructose-enriched Diet on Serum Metabolome by Normal- and Over-weighed Women. Completed NCT03444233 Phase 4
22 Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes Completed NCT02637973 Phase 4 Empagliflozin;Placebo
23 Study on Effects of Testosterone Replacement Therapy in Hypogonadal Type 2 Diabetic Patients" (SETH2) Completed NCT03792321 Phase 4 Testosterone Undecanoate;Placebo
24 Pioglitazone in Hepatitis C Completed NCT00189163 Phase 4 Pioglitazone;Placebo Oral Tablet
25 Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes Completed NCT00998335 Phase 4 Long-acting bedtime insulin detemir (Levemir);Insulin detemir and pre-meal insulin aspart.
26 Weight Loss Improves Renal Hemodynamics Completed NCT01356394 Phase 4
27 Mechanism of Fatty Acid-induced Impairment of Glucose-simulated Insulin Secretion - Effect of Buphenyl Completed NCT00533559 Phase 4 sodium phenylbutyrate;Placebo
28 Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) Completed NCT00227110 Phase 4 Pioglitazone;Placebo
29 Anti-fatigue Effect of Korean Red Ginseng in Patients With Non-alcoholic Hepatitis Completed NCT02331589 Phase 4 KRG (Korea Red ginseng);Placebo (for KRG)
30 Effects of Siliphos-Selenium-Methionine-Alpha Lipoic Acid in Patients With Fatty Liver and Non-alcoholic Steatohepatitis Completed NCT01650181 Phase 4 Metformin;Metformin
31 Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT00160407 Phase 4 Orlistat (Xenical)
32 A Randomized, Prospective, Open Label, Active Control, Phase IV Study to Evaluate the Effects of Statin Monotherapy or Statin / Ezetimibe Combination Therapy on Hepatic Steatosis in Patients With Hyperlipidemia and Nonalcoholic Fatty Liver Disease Recruiting NCT03434613 Phase 4 Rosuvastatin;Rosuvastatin/ezetimibe combination
33 SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD Recruiting NCT02649465 Phase 4 Tofogliflozin;Glimepiride
34 Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS) Recruiting NCT02500147 Phase 4 Metformin;Placebo
35 The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes Recruiting NCT02964715 Phase 4 Empagliflozin
36 The Potential Hepatoprotective Effect of Metformin in Patients With Beta Thalassemia Major Recruiting NCT02984475 Phase 4 Metformin
37 Efficacy of Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets on the Patients With Newly Diagnosed Type 2 Diabetes Mellitus Combined With Non-alcoholic Fatty Liver Disease Active, not recruiting NCT03796975 Phase 4 Combination of Pioglitazone and Metformin Tablets;Metformin Hydrochloride Tablets
38 The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease Active, not recruiting NCT03222206 Phase 4 Salsalate
39 Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Mono-infected Patients Enrolling by invitation NCT02210715 Phase 4 Isentress.
40 Comparison of The Effects of Thiazolidinediones(TZD), Sodium- Glucose Cotransporter 2 Inhibitors(SGLT2i) Alone and TZD / SGLT2i Combination Therapy on Non-alcoholic Fatty Liver Disease in Type 2 Diabetic Patients With Fatty Liver Not yet recruiting NCT03646292 Phase 4 Pioglitazone;Empagliflozin;Combination of pioglitazone and empagliflozin
41 Silymarin in NAFLD Not yet recruiting NCT02973295 Phase 4 Silymarin
42 Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis Not yet recruiting NCT03198572 Phase 4 Placebo;Berberine
43 Researching an Effect of GLP-1 Agonist on Liver STeatosis (REALIST) Not yet recruiting NCT03648554 Phase 4 dulaglutide (TRULICITY®) 1.5 mg
44 High-intensity Rosuvastatin vs. Moderate-intensity Rosuvastatin/Ezetimibe in High Atherosclerotic Cardiovascular Disease Risk Patients With Type 2 Diabetes Not yet recruiting NCT03403556 Phase 4 Rosuvamibe;Monorova
45 Study to Assess Efficacy of Besifovir and L-carnitine in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver Not yet recruiting NCT03604016 Phase 4 Besifovir dipivoxil;L-carnitine;Tenofovir Alafenamide
46 Rifaximin in Fatty Liver Disease Terminated NCT01355575 Phase 4 Rifaximin
47 Metformin for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) Terminated NCT00736385 Phase 4 Glucophage (Metformin);Placebo
48 Assessing the Efficacy and Safety of Rosiglitazone Added to Standard Therapy for Hepatitis C Genotype 1 With Fatty Liver Terminated NCT00274495 Phase 4 Rosiglitazone and Pegasys/Ribavirin
49 Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH Terminated NCT01406704 Phase 4 Rosiglitazone;alpha-lipoic acid;Rosiglitazone/alpha-lipoic acid
50 Fatty Liver Study in Patients With Type II Diabetes Terminated NCT02365233 Phase 4 DPP4 inhibitor;Pioglitazone;Lantus insulin

Search NIH Clinical Center for Fatty Liver Disease

Cochrane evidence based reviews: fatty liver

Sources

Genetic Tests for Fatty Liver Disease

About this section
Sources

Anatomical Context for Fatty Liver Disease

About this section

MalaCards organs/tissues related to Fatty Liver Disease:

41
Liver, Testes, Heart, Kidney, Endothelial, Ovary, Bone
Sources

Publications for Fatty Liver Disease

About this section

Articles related to Fatty Liver Disease:

(show top 50) (show all 4394)
# Title Authors Year
1
Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non-alcoholic fatty liver disease. ( 30430605 )
2019
2
The Future of Nonalcoholic Fatty Liver Disease Treatment. ( 30466676 )
2019
3
Fatty liver disease: is it nonalcoholic fatty liver disease or obesity-associated fatty liver disease? ( 30507644 )
2019
4
Vitamin E alleviates non-alcoholic fatty liver disease in phosphatidylethanolamine N-methyltransferase deficient mice. ( 30300671 )
2019
5
Olive oil lessened fatty liver severity independent of cardiometabolic correction in patients with non-alcoholic fatty liver disease: A randomized clinical trial. ( 30170304 )
2019
6
Serum biomarkers of fibrosis and extracellular matrix remodeling in patients with nonalcoholic fatty liver disease: association with liver histology. ( 30134384 )
2019
7
Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver Disease. ( 30016770 )
2019
8
The Pattern of Elevated Liver Function Tests in Nonalcoholic Fatty Liver Disease Predicts Fibrosis Stage and Metabolic-Associated Comorbidities. ( 30016799 )
2019
9
Progress and challenges in the prevention and control of nonalcoholic fatty liver disease. ( 29846945 )
2019
10
Obestatin protects and reverses nonalcoholic fatty liver disease and its associated insulin resistance in rats via inhibition of food intake, enhancing hepatic adiponectin signaling, and blocking ghrelin acylation. ( 29429367 )
2018
11
Simultaneous quantification of hepatic MRI-PDFF and R2* in a rabbit model with nonalcoholic fatty liver disease. ( 29934919 )
2018
12
Chicory (Cichorium intybus L.) polysaccharides attenuate high-fat diet induced non-alcoholic fatty liver disease via AMPK activation. ( 29964102 )
2018
13
Taurine attenuates the development of hepatic steatosis through the inhibition of oxidative stress in a model of nonalcoholic fatty liver disease in vivo and in vitro. ( 29946793 )
2018
14
Nonalcoholic Fatty Liver Disease: Time to Take the Bull by the Horns. ( 29963461 )
2018
15
Role of genetic and metabolism in non-alcoholic fatty liver disease. ( 29442484 )
2018
16
Effects of isomaltulose on insulin resistance and metabolites in patients with nona89alcoholic fatty liver disease: A metabolomic analysis. ( 29956790 )
2018
17
Noninvasive Quantitative Detection Methods of Liver Fat Content in Nonalcoholic Fatty Liver Disease. ( 29951367 )
2018
18
PNPLA3: A Determinant of Response to Low-Fructose Diet in Nonalcoholic Fatty Liver Disease. ( 29452087 )
2018
19
A Case-control Study to Evaluate the Prevalence of Nonalcoholic Fatty Liver Disease Among Patients with Moderate-to-severe Psoriasis. ( 29942422 )
2018
20
Exploring the relationship between nonalcoholic fatty liver disease and pancreatic cancer by computed tomographic survey. ( 29235054 )
2018
21
Statin Use In Cirrhosis from Fatty Liver Disease. ( 29443384 )
2018
22
Urea cycle dysregulation in non-alcoholic fatty liver disease. ( 29981428 )
2018
23
Practical Dietary Recommendations for the Prevention and Management of Nonalcoholic Fatty Liver Disease in Adults. ( 29438460 )
2018
24
The Fatty Liver Index: A Simple and Accurate Predictor of Colorectal Adenoma in an Average-Risk Population. ( 29219920 )
2018
25
Hepatic loss of <i>Lissencephaly 1</i> (<i>Lis1</i>) induces fatty liver and accelerates liver tumorigenesis in mice. ( 29475944 )
2018
26
Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Why liver biopsy is essential. ( 29427497 )
2018
27
Validation of simple indexes for nonalcoholic fatty liver disease in western China: a retrospective cross-sectional study. ( 29434074 )
2018
28
Personalized therapy when tackling nonalcoholic fatty liver disease: a focus on sex, genes, and drugs. ( 29969922 )
2018
29
Risk factors and metabolic abnormality of patients with non-alcoholic fatty liver disease: Either non-obese or obese Chinese population. ( 29428103 )
2018
30
The Influence of Gut Microbial Metabolism on the Development and Progression of Non-alcoholic Fatty Liver Disease. ( 29956209 )
2018
31
Normal serum alanine aminotransferase and non-alcoholic fatty liver disease among Korean adolescents: a cross-sectional study using data from KNHANES 2010-2015. ( 29976192 )
2018
32
Correction: Prospective comparison among transient elastography, supersonic shear imaging, and ARFI imaging for predicting fibrosis in nonalcoholic fatty liver disease. ( 29944727 )
2018
33
Changes in inflammatory factors and prognosis of patients complicated with non-alcoholic fatty liver disease undergoing coronary artery bypass grafting. ( 29434690 )
2018
34
Pathogenesis of NASH: How Metabolic Complications of Overnutrition Favour Lipotoxicity and Pro-Inflammatory Fatty Liver Disease. ( 29956204 )
2018
35
Future therapy for non-alcoholic fatty liver disease. ( 29427492 )
2018
36
Evaluation of nonalcoholic fatty liver disease using magnetic resonance in obese children and adolescents. ( 29438686 )
2018
37
Non-alcoholic fatty liver disease severity is modulated by transglutaminase type 2. ( 29449533 )
2018
38
Origins of Portal Hypertension in Nonalcoholic Fatty Liver Disease. ( 29368124 )
2018
39
Daily Consumption of Synbiotic Yogurt Decreases Liver Steatosis in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial. ( 29931231 )
2018
40
Huperzine A attenuates nonalcoholic fatty liver disease by regulating hepatocyte senescence and apoptosis: an in vitro study. ( 29967757 )
2018
41
Serine/threonine protein kinase 25 antisense oligonucleotide treatment reverses glucose intolerance, insulin resistance, and nonalcoholic fatty liver disease in mice. ( 29404514 )
2018
42
Decreased Hepatic Lactotransferrin Induces Hepatic Steatosis in Chronic Non-Alcoholic Fatty Liver Disease Model. ( 29975946 )
2018
43
Nonalcoholic fatty liver disease burden - Saudi Arabia and United Arab Emirates, 2017-2030. ( 29956688 )
2018
44
Alcohol Dehydrogenase Isoenzymes and Aldehyde Dehydrogenase Activity in the Serum of Patients with Non-alcoholic Fatty Liver Disease. ( 29970524 )
2018
45
Associations of hyperuricemia and obesity with remission of nonalcoholic fatty liver disease among Chinese men: A retrospective cohort study. ( 29415050 )
2018
46
Chronic heart failure in patients with nonalcoholic fatty liver disease: prevalence, clinical features, and relevance. ( 29968484 )
2018
47
Relationship between diverticulosis and nonalcoholic fatty liver disease in elderly patients. ( 29432700 )
2018
48
Intestinal Microbiome Shifts, Dysbiosis, Inflammation, and Non-alcoholic Fatty Liver Disease. ( 29441049 )
2018
49
A comprehensive bioinformatics analysis on multiple Gene Expression Omnibus datasets of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. ( 29769552 )
2018
50
<i>Helicobacter pylori</i> Infection Is Not Associated with Non-alcoholic Fatty Liver Disease: A Cross-Sectional Study in China. ( 29445363 )
2018
Sources

Variations for Fatty Liver Disease

About this section
Sources

Expression for Fatty Liver Disease

About this section
Search GEO for disease gene expression data for Fatty Liver Disease.
Sources

Pathways for Fatty Liver Disease

About this section

Pathways related to Fatty Liver Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Super pathways Score Top Affiliating Genes
1
Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. 66
Show member pathways
 13.53 ADIPOQ ADIPOR1 ADIPOR2 CYP2E1 IL1B IL6
2
Developmental Biology 66
Show member pathways
 13.51 ADIPOQ INS IRS1 IRS2 LEP PPARA
3
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 65
Show member pathways
 12.73 ADIPOQ IL6 INS IRS1 IRS2 LEP
4
Immune response IL-23 signaling pathway 22
Show member pathways
 12.59 IL1B IL6 IRS2 MAPK8 TNF
5
Glucose / Energy Metabolism 4
12.54 ADIPOQ INS IRS1 IRS2 SREBF1
6
Angiopoietin Like Protein 8 Regulatory Pathway 1
Show member pathways
 12.49 INS IRS1 IRS2 MAPK8 MLXIPL NR1H3
7
Prolactin Signaling Pathway 1 37
Show member pathways
 12.47 IL1B INS IRS1 IRS2 LEP LEPR
8
AMP-activated Protein Kinase (AMPK) Signaling 1
Show member pathways
 12.44 ADIPOQ ADIPOR1 ADIPOR2 INS IRS1 IRS2
9
T cell receptor signaling pathway 37
Show member pathways
 12.43 IL1B IL6 MAPK8 TNF
10
Human T-cell leukemia virus 1 infection 37
12.43 IL6 MAPK8 TNF XBP1
11
Selenium Micronutrient Network 1
Show member pathways
 12.34 IL1B IL6 INS TNF
12
IL-17 Family Signaling Pathways 65
Show member pathways
 12.34 IL1B IL6 MAPK8 TNF
13
Integration of energy metabolism 66
Show member pathways
 12.34 ADIPOQ ADIPOR1 ADIPOR2 INS MLXIPL
14
Toll Comparative Pathway 64
Show member pathways
 12.32 IL1B IL6 MAPK8 TNF
16
Apoptosis and survival Caspase cascade 22
Show member pathways
 12.28 IRS1 MAPK8 SREBF1 TNF
17
Tuberculosis 37
12.24 IL1B IL6 MAPK8 TNF
18
IL-1 Family Signaling Pathways 65
Show member pathways
 12.23 IL1B IL6 MAPK8 TNF
19
C-type lectin receptor signaling pathway 37
Show member pathways
 12.22 IL1B IL6 MAPK8 TNF
20
AMPK Enzyme Complex Pathway 64
Show member pathways
 12.21 INS IRS1 IRS2 LEP
21
Longevity regulating pathway 37
Show member pathways
 12.15 ADIPOQ ADIPOR1 ADIPOR2 INS IRS1 IRS2
22
Adipogenesis 1
12.12 ADIPOQ IL6 INS IRS1 IRS2 LEP
23
Hepatitis C 37
12.06 MAPK8 NR1H3 PPARA TNF
24
FoxO signaling pathway 37
Show member pathways
 12.06 IL6 INS IRS1 IRS2 MAPK8
25
Autophagy - animal 37
12.03 INS IRS1 IRS2 MAPK8
26
Spinal Cord Injury 1
11.99 IL1B IL6 LEP TNF
27
TNF signaling pathway 37
11.93 IL1B IL6 MAPK8 TNF
28
Type II diabetes mellitus 37 1
Show member pathways
 11.89 ADIPOQ INS IRS1 IRS2 MAPK8 TNF
29
AGE-RAGE signaling pathway in diabetic complications 37
11.88 IL1B IL6 MAPK8 TNF
30
Rheumatoid arthritis 37
11.86 IL1B IL6 TNF
31
Salmonella infection (KEGG) 37
11.83 IL1B IL6 MAPK8
32
Dendritic Cells Developmental Lineage Pathway 65
11.76 IL1B IL6 TNF
33
PPAR signaling pathway 37
11.76 ADIPOQ NR1H3 PPARA
34
Microglia Activation During Neuroinflammation: Microglia Polarization 65
11.74 IL1B IL6 TNF
35
Pertussis 37
11.74 IL1B IL6 MAPK8 TNF
36
AGE/RAGE pathway 1
11.7 INS IRS1 MAPK8
37
Adipocytokine signaling pathway 37
11.69 ADIPOQ ADIPOR1 ADIPOR2 IRS1 IRS2 LEP
38
Insulin resistance 37
Show member pathways
 11.69 IL6 INS IRS1 IRS2 MAPK8 MLXIPL
39
Lung fibrosis 1
11.68 IL1B IL6 TNF
40
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.68 IL1B IL6 TNF
41
ATF-2 transcription factor network 1
11.61 IL6 INS MAPK8
42
Legionellosis 37
11.61 IL1B IL6 TNF
43
Regulation of lipolysis in adipocytes 37
11.6 INS IRS1 IRS2
44
Photodynamic therapy-induced AP-1 survival signaling. 1
11.56 IL6 MAPK8 TNF
45
Development_Leptin signaling via PI3K-dependent pathway 22
11.56 IRS1 IRS2 LEP LEPR
46
Interleukin-10 signaling 66
11.54 IL1B IL6 TNF
47
Signaling events mediated by PTP1B 1
11.54 INS IRS1 LEP LEPR
48
Malaria 37
11.53 IL1B IL6 TNF
49
Transcription_Role of VDR in regulation of genes involved in osteoporosis 22
11.49 IL1B IL6 TNF
50
Signaling events regulated by Ret tyrosine kinase 1
11.41 IRS1 IRS2 MAPK8
Sources

GO Terms for Fatty Liver Disease

About this section

Biological processes related to Fatty Liver Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 77)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.98 IL1B IL6 INS TNF
2 lipid metabolic process GO:0006629 9.97 ADIPOR1 ADIPOR2 LEP NR1H3 PNPLA3 PPARA
3 response to ethanol GO:0045471 9.96 ADIPOQ CYP2E1 IL1B LEP
4 positive regulation of protein kinase B signaling GO:0051897 9.96 INS IRS1 IRS2 LEP TNF
5 regulation of lipid metabolic process GO:0019216 9.93 ADIPOR1 IRS2 PPARA
6 circadian rhythm GO:0007623 9.93 ADIPOQ LEP SREBF1
7 insulin receptor signaling pathway GO:0008286 9.93 INS IRS1 IRS2 SREBF1
8 cholesterol metabolic process GO:0008203 9.92 LEP LEPR SREBF1
9 response to nutrient GO:0007584 9.92 ADIPOQ ADIPOR2 LEP
10 response to glucose GO:0009749 9.91 ADIPOQ IRS2 SREBF1
11 response to insulin GO:0032868 9.91 IRS1 LEP PPARA
12 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.91 INS LEP TNF
13 cellular response to glucose stimulus GO:0071333 9.9 IL1B IRS2 XBP1
14 positive regulation of T cell proliferation GO:0042102 9.89 IL1B IL6 LEP
15 positive regulation of interleukin-6 production GO:0032755 9.89 IL1B IL6 TNF
16 response to peptide hormone GO:0043434 9.88 IL1B IRS1 SREBF1
17 hormone-mediated signaling pathway GO:0009755 9.88 ADIPOR1 ADIPOR2 PPARA
18 regulation of insulin secretion GO:0050796 9.88 IL1B LEP SREBF1 TNF
19 response to glucocorticoid GO:0051384 9.88 ADIPOQ IL1B IL6 TNF
20 regulation of circadian rhythm GO:0042752 9.87 MAPK8 NR1H3 PPARA
21 negative regulation of fat cell differentiation GO:0045599 9.87 ADIPOQ IL6 TNF
22 intracellular receptor signaling pathway GO:0030522 9.85 NR1H3 PPARA SREBF1
23 lipid homeostasis GO:0055088 9.85 IRS2 NR1H3 PNPLA3
24 positive regulation of cold-induced thermogenesis GO:0120162 9.85 ADIPOQ ADIPOR1 ADIPOR2 LEP LEPR
25 positive regulation of interleukin-8 production GO:0032757 9.83 ADIPOQ IL1B TNF
26 positive regulation of JAK-STAT cascade GO:0046427 9.83 ADIPOR1 IL6 LEP
27 cellular response to insulin stimulus GO:0032869 9.83 ADIPOQ IRS1 IRS2 SREBF1 XBP1
28 negative regulation of neurogenesis GO:0050768 9.82 IL1B IL6 TNF
29 negative regulation of lipid catabolic process GO:0050995 9.8 IL1B INS TNF
30 positive regulation of cellular protein metabolic process GO:0032270 9.8 ADIPOQ INS NR1H3
31 cellular response to lipopolysaccharide GO:0071222 9.8 IL1B IL6 MAPK8 NR1H3 TNF XBP1
32 positive regulation of glial cell proliferation GO:0060252 9.79 IL1B IL6 TNF
33 positive regulation of glycogen biosynthetic process GO:0045725 9.79 INS IRS1 IRS2
34 fatty acid homeostasis GO:0055089 9.77 INS MLXIPL XBP1
35 fatty acid oxidation GO:0019395 9.77 ADIPOQ ADIPOR1 ADIPOR2
36 regulation of protein secretion GO:0050708 9.75 INS TNF
37 positive regulation of immunoglobulin secretion GO:0051024 9.75 IL6 XBP1
38 positive regulation of triglyceride biosynthetic process GO:0010867 9.75 NR1H3 SREBF1
39 positive regulation of monocyte chemotactic protein-1 production GO:0071639 9.74 ADIPOQ IL1B
40 sexual reproduction GO:0019953 9.74 LEP LEPR
41 positive regulation of glucose metabolic process GO:0010907 9.74 IRS1 IRS2
42 negative regulation of gluconeogenesis GO:0045721 9.74 ADIPOQ INS LEPR
43 negative regulation of appetite GO:0032099 9.73 LEP PPARA
44 negative regulation of synaptic transmission GO:0050805 9.73 ADIPOQ IL1B
45 negative regulation of cholesterol storage GO:0010887 9.73 NR1H3 PPARA
46 positive regulation of chemokine biosynthetic process GO:0045080 9.72 IL1B TNF
47 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.72 ADIPOQ NR1H3 PPARA
48 interleukin-6 production GO:0032635 9.71 IL1B LEP
49 regulation of establishment of endothelial barrier GO:1903140 9.71 IL1B TNF
50 regulation of fatty acid metabolic process GO:0019217 9.71 PPARA SREBF1

Molecular functions related to Fatty Liver Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.83 MLXIPL NR1H3 PPARA SREBF1 XBP1
2 signaling receptor activity GO:0038023 9.76 ADIPOR1 ADIPOR2 NR1H3 PPARA
3 cytokine activity GO:0005125 9.71 ADIPOQ IL1B IL6 TNF
4 RNA polymerase II regulatory region sequence-specific DNA binding GO:0000977 9.65 NR1H3 PPARA SREBF1 TNF XBP1
5 nuclear receptor activity GO:0004879 9.54 NR1H3 PPARA SREBF1
6 adiponectin binding GO:0055100 9.32 ADIPOR1 ADIPOR2
7 adipokinetic hormone receptor activity GO:0097003 9.16 ADIPOR1 ADIPOR2
8 sterol response element binding GO:0032810 8.96 NR1H3 SREBF1
9 insulin receptor binding GO:0005158 8.8 INS IRS1 IRS2
Sources

Sources for Fatty Liver Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....